Which of the following is NOT a finding of disseminated intravascular coagulation: thrombocytopenia, hypofibrinogenemia, fibrin degradation products, target cells, or schistocytes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Target Cells Are NOT a Finding of Disseminated Intravascular Coagulation

The correct answer is d. target cells—these are NOT associated with DIC. Target cells are morphologic red blood cell abnormalities seen in conditions such as liver disease, thalassemia, hemoglobinopathies, and post-splenectomy states, but they are not part of the DIC laboratory picture. 1, 2

Classic Laboratory Findings in DIC

The hallmark laboratory abnormalities in DIC reflect the underlying pathophysiology of consumptive coagulopathy and microangiopathic hemolysis:

Thrombocytopenia (Option a - IS a finding)

  • Platelet consumption from widespread intravascular clotting is a characteristic and essential laboratory finding in DIC. 1, 2
  • Thrombocytopenia occurs in approximately 75% of DIC patients and represents the most common laboratory abnormality. 3
  • Even a 30% or greater drop in platelet count from baseline is diagnostic of subclinical DIC, even when absolute values remain within normal range. 2

Hypofibrinogenemia/Fibrinogenopenia (Option b - IS a finding)

  • Decreased fibrinogen levels develop in advanced DIC cases due to consumption of coagulation factors. 1, 2
  • While fibrinogen may initially be normal or even elevated as an acute phase reactant early in the disease process, progressive consumption leads to hypofibrinogenemia. 1
  • Low fibrinogen is one of the core components of the ISTH DIC diagnostic scoring system. 3, 2

Fibrin/Fibrinogen Degradation Products (Option c - IS a finding)

  • Elevated fibrin-related markers (D-dimer and fibrin degradation products) indicating ongoing fibrin formation and breakdown are characteristic laboratory findings in DIC. 1, 2
  • These markers reflect the simultaneous activation of coagulation and fibrinolysis that defines DIC pathophysiology. 3
  • D-dimer is highly sensitive for DIC diagnosis and is included in all major DIC scoring systems. 3, 2

Schistocytes (Option e - IS a finding)

  • Schistocytes (fragmented red blood cells) are frequently observed in DIC patients, resulting from mechanical shearing of red blood cells as they pass through fibrin strands in the microvasculature. 4, 5
  • Schistocytes were present in 30 of 35 DIC patients (86%) in one study, though typically at low percentages (mean 0.33%, median 0.1%). 4
  • While the percentage is usually low and within or close to reference range (<0.5%), schistocytes ≥1% suggest an associated thrombotic microangiopathy. 4
  • The presence of schistocytes reflects microangiopathic hemolysis, which is part of the consumptive process in DIC. 6, 5

Why Target Cells Don't Fit

Target cells represent a fundamentally different pathophysiologic process—they are morphologic abnormalities related to altered hemoglobin distribution or membrane lipid composition, not mechanical fragmentation or consumption. They have no role in the diagnosis or monitoring of DIC and would not be expected in this condition unless there is a concurrent unrelated disorder (such as underlying liver disease). 3

References

Guideline

Disseminated Intravascular Coagulation Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Laboratory Tests for Diagnosing and Managing Disseminated Intravascular Coagulation (DIC)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Schistocytes in disseminated intravascular coagulation.

International journal of laboratory hematology, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.